Year

2015
2,000L Demonstration Batch Completed at Lonza, Houston FacilitySAN DIEGO, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has conducted initial scale up of its viral manufacturing process for MYDICAR (AAV1/SERCA2a) to commercial scale.
SAN DIEGO, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has been added to the NASDAQ Biotechnology Index, through the annual update that will become effective prior to market open on Monday, December 22, 2014.The NASDAQ...
1 10 11 12

Nyheder

Giftslanger: Forskere finder smart modgift-cocktail
2. oktober 2018
Nyt panel skal udpege Lundbeckfondens største hjernesatsninger
1. oktober 2018
Laks og markmus skal gøre os klogere på gådefuldt hologenom
28. september 2018

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge